ABVC BIOPHARMA, INC.

ABVC BioPharma, Inc. is an early-stage biotechnology enterprise that develops botanical drugs and medical devices addressing central nervous system disorders and oncology diseases. The company generates revenue by outlicensing its intellectual property and providing contract development and manufacturing organization (CDMO) services through its subsidiary BioKey, which produces active pharmaceutical ingredients, capsules, tablets, and oral liquids for clinical trials. Its development pipeline features botanical drug candidates targeting conditions such as major depressive disorder, attention-deficit hyperactivity disorder, and depression in cancer patients, alongside the Vitargus medical device for vitrectomy procedures and a commercial dietary supplement line derived from maitake mushrooms.

The company focuses on sourcing therapeutic innovations from research institutions in the Asia-Pacific region and conducts multi-center clinical trials across the United States, Taiwan, Australia, and Thailand. Operational facilities include a certified Good Manufacturing Practice manufacturing site located in California. ABVC BioPharma maintains its corporate headquarters in Fremont, California.

Summary of the business section of Abvc Biopharma's latest annual report, written by StockData.

“As of December 31, 2025, we, including the subsidiaries, have 19 employees, 16 of which are full-time, located in the U.S.”